In order to understand the biological mechanisms important in the inhibition of breast cancer cell growth and progression by FOXM1 inhibitors, we studied ER-positive and triple negative breast cancer cells sensitive to FOXM1 inhibitors, and we also developed long-term treated cells that acquired resistance to growth suppression by these inhibitors. The gene discussed is ESR1; the disease is breast carcinoma.